Alicia Algeciras-Schimnich

Jun 24, 2024 | mayoclinicproceedings.org | Wentao Li |Ronald Petersen |Alicia Algeciras-Schimnich

Abstract To evaluate the performance of Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in a tertiary neurology clinic setting with high frequency of non-AD cases, including normal pressure hydrocephalus (NPH). There were 534 patients who underwent AD CSF biomarkers (Roche Elecsys Aβ42, p-Tau181, total-Tau) from April 1, 2020, through April 23, 2021.